Lilly takes long view on Alzheimer’s drug hopeful as FDA starts expedited review

The Food and Drug Administration has agreed to an expedited review of Eli Lilly’s experimental Alzheimer’s disease medicine donanemab, the pharmaceutical company said Thursday.